Sentinel Capital Partners, a private equity firm that invests in promising companies in the lower mid-market, has sold WellSpring Pharma Services, a North American pharmaceutical contract manufacturing organisation. Terms of the deal have not been disclosed.
WellSpring Pharma Services provides outsourced manufacturing and contract development services to emerging-growth, mid-sized, and large pharmaceutical and biotechnology clients in the US and Canada. WellSpring has particular strength working with clients that need flexibility, customisation, personalised attention, and technical expertise. WellSpring is equipped to manufacture prescription drug products in virtually all non-sterile finished dosage forms and also provides primary and secondary packaging services. WellSpring also offers formulation, tech transfer, and analytical chemistry services to its clients.
“Trends in the pharmaceutical industry have continued to drive demand for WellSpring’s manufacturing services,” says John Van Sickle, a Sentinel partner. “WellSpring addresses this demand with an industry-recognised commitment to quality and regulatory compliance.”
At the outset of Sentinel’s 2011 investment, WellSpring consisted of three divisions: a consumer portfolio of over-the-counter health and personal care products; a portfolio of specialty prescription drugs; and a contract manufacturer of pharmaceutical products. Under Sentinel’s ownership, WellSpring sharpened its focus by divesting its specialty Rx portfolio and bolstering the market position of its consumer healthcare portfolio with three OTC add-ons. WellSpring then sold its consumer healthcare business in 2017. The sale of WellSpring Pharma Services completes Sentinel’s final exit from its original WellSpring investment.